In the article cited above, a composition error resulted in the omission of references 30–35, and the reference Cusi et al. was listed as reference 30. The reference number for Cusi et al. is 36, and the correct references 30–35 are as follows:

Scholtes RA, Muskiet MHA, van Baar MJB, et al. Natriuretic effect of two weeks of dapagliflozin treatment in patients with type 2 diabetes and preserved kidney function during standardized sodium intake: results of the DAPASALT trial. Diabetes Care 2021;44:440–447

Petersen MC, Vatner DF, Shulman GI. Regulation of hepatic glucose metabolism in health and disease. Nat Rev Endocrinol 2017;13:572–587

Wefers J, Connell NJ, Fealy CE, et al. Daynight rhythm of skeletal muscle metabolism is disturbed in older, metabolically compromised individuals. Mol Metab 2020;41:101050

Lin X, Zhang X, Guo J, et al. Effects of exercise training on cardiorespiratory fitness and biomarkers of cardiometabolic health: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc 2015;4:e002014

Mudaliar S, Henry RR, Boden G, et al. Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin. Diabetes Technol Ther 2014;16:137–144

Tuominen JA, Ebeling P, Bourey R, et al. Postmarathon paradox: insulin resistance in the face of glycogen depletion. Am J Physiol 1996;270:E336–E343

The online version of the article ( has been updated with the correct references.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at